Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ECLIPSE 3: Tobevibart + Elebsiran vs Bulevirtide in Chronic HDV Infection
2024-520062-54-00Phase 2Authorised
- Sponsor
- Vir Biotechnology
- Start
- Jun 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 13
01
Overview
Phase 2, randomised, open-label trial in hepatitis D (HDV) comparing Tobevibart + Elebsiran arm with Bulevirtide (Hepcludex) arm (2 arms). Primary endpoints: Primary virologic response Part 1, Primary virologic response Part 2 and 1 more. Planned start Jun 2025; status: authorised.
02
Drugs
tobevibartelebsiranbulevirtide
03
Conditions
hepatitis D (HDV)
Beyond the preview
Go deeper on 2024-520062-54-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-520062-54-00.